ACADIA Pharmaceuticals - ACAD Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $21.44
Forecasted Upside: 13.88%
Number of Analysts: 17
Breakdown:
2 Sell Ratings
6 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$18.83 As of 03/22/2023 03:08 PM ET

▼ -0.62 (-3.19%)

1 month | 3 months | 12 months

Get New ACADIA Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ACAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACAD

^$21.44

▲ +13.88% Upside Potential

This price target is based on 17 analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $21.44, with a high forecast of $33.00 and a low forecast of $12.00. The average price target represents a 13.88% upside from the last price of $18.83.

Current Consensus is Hold

The current consensus among 17 contributing investment analysts is to hold stock in ACADIA Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
8 hold ratings
2 sell ratings

Ratings as of

9/28/2021

0 strong buy ratings
7 buy ratings
9 hold ratings
2 sell ratings

Ratings as of

12/27/2021

0 strong buy ratings
8 buy ratings
8 hold ratings
2 sell ratings

Ratings as of

3/27/2022

0 strong buy ratings
9 buy ratings
7 hold ratings
2 sell ratings

Ratings as of

6/25/2022

0 strong buy ratings
10 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

9/23/2022

0 strong buy ratings
9 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

12/22/2022

0 strong buy ratings
10 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

2/20/2023

0 strong buy ratings
9 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

3/22/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/14/2023	Canaccord Genuity Group	Boost Target	Buy	$24.00 ➝ $26.00	Low
3/14/2023	Royal Bank of Canada	Reiterated Rating	Outperform	$27.00	Low
3/14/2023	Morgan Stanley	Boost Target	Equal Weight	$19.00 ➝ $20.00	Low
3/14/2023	Guggenheim	Boost Target		$22.00 ➝ $25.00	Low
3/14/2023	Jefferies Financial Group	Boost Target		$10.00 ➝ $15.00	Low
3/14/2023	Mizuho	Boost Target		$19.00 ➝ $20.00	Low
3/14/2023	Cantor Fitzgerald	Boost Target	Overweight	$28.00 ➝ $33.00	Low
3/14/2023	Citigroup	Boost Target	Neutral	$19.40 ➝ $21.00	Low
3/14/2023	HC Wainwright	Boost Target	Buy	$25.00 ➝ $28.00	Low
3/13/2023	Mizuho	Reiterated Rating	Neutral	$19.00	Low
3/1/2023	Oppenheimer	Boost Target	Market Perform	$17.00 ➝ $20.00	Low
2/28/2023	Citigroup	Boost Target	Neutral	$19.00 ➝ $19.40	Low
2/28/2023	JMP Securities	Lower Target	Market Perform	$24.00 ➝ $22.00	Low
2/28/2023	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
2/28/2023	Morgan Stanley	Boost Target	Equal Weight	$18.00 ➝ $19.00	Low
2/28/2023	Royal Bank of Canada	Boost Target	Outperform	$19.00 ➝ $27.00	Low
2/28/2023	Mizuho	Boost Target	Neutral	$15.00 ➝ $19.00	Low
2/15/2023	Oppenheimer	Boost Target	Market Perform	$16.00 ➝ $17.00	Low
1/31/2023	Citigroup	Boost Target	Neutral	$17.00 ➝ $19.00	Low
1/3/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$22.00	Low
12/21/2022	Mizuho	Lower Target	Neutral	$17.00 ➝ $15.00	Low
11/14/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$19.00 ➝ $17.00	Low
11/3/2022	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell	$15.00 ➝ $12.00	Low
11/3/2022	Royal Bank of Canada	Lower Target	Outperform	$22.00 ➝ $21.00	Low
11/1/2022	Loop Capital	Initiated Coverage	Hold	$17.00	Low
10/18/2022	HC Wainwright	Reiterated Rating	Buy	$25.00	Low
10/13/2022	Mizuho	Lower Target		$17.00	Low
10/7/2022	Mizuho	Lower Target		$19.00 ➝ $17.00	Low
8/9/2022	Morgan Stanley	Lower Target	Equal Weight	$22.00 ➝ $18.00	Low
8/9/2022	The Goldman Sachs Group	Lower Target	Neutral	$20.00 ➝ $15.00	Low
8/9/2022	Royal Bank of Canada	Lower Target	Outperform	$26.00 ➝ $21.00	Low
8/9/2022	Mizuho	Lower Target	Neutral	$27.00 ➝ $19.00	Low
8/9/2022	HC Wainwright	Boost Target	Buy	$20.00 ➝ $25.00	Low
8/9/2022	Citigroup	Boost Target		$15.00 ➝ $17.00	Low
8/9/2022	SVB Leerink	Lower Target	Outperform	$27.00 ➝ $21.00	Low
8/8/2022	Cowen	Lower Target	Outperform	$32.00 ➝ $21.00	Low
8/8/2022	Cowen	Lower Target	Outperform	$32.00 ➝ $21.00	Low
8/5/2022	Citigroup	Downgrade	Buy ➝ Neutral	$19.00 ➝ $15.00	Low
7/15/2022	Morgan Stanley	Lower Target	Equal Weight	$24.00 ➝ $22.00	Low
7/11/2022	SVB Leerink	Lower Target	Outperform	$31.00 ➝ $27.00	N/A
6/22/2022	Canaccord Genuity Group	Lower Target		$31.00 ➝ $20.00	Low
6/22/2022	Citigroup	Lower Target	Buy	$32.00 ➝ $19.00	Low
6/21/2022	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low
6/21/2022	Jefferies Financial Group	Downgrade	Buy ➝ Underperform	$25.00 ➝ $10.00	Low
6/21/2022	Royal Bank of Canada	Lower Target	Outperform	$32.00 ➝ $26.00	Low
6/21/2022	Oppenheimer	Lower Target	Market Perform	$23.00 ➝ $19.00	Low
6/21/2022	Cantor Fitzgerald	Lower Target	Overweight	$37.00 ➝ $26.00	Low
6/21/2022	HC Wainwright	Lower Target	Buy	$36.00 ➝ $20.00	Low
6/16/2022	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$25.00	High
4/19/2022	Mizuho	Lower Target	Neutral	$28.00 ➝ $27.00	High
3/18/2022	Morgan Stanley	Reiterated Rating	Hold	$24.00	Medium
3/16/2022	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$30.00 ➝ $31.00	Low
3/16/2022	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$30.00 ➝ $31.00	Low
3/10/2022	Cantor Fitzgerald	Boost Target	Overweight	$32.00 ➝ $37.00	High
3/7/2022	The Goldman Sachs Group	Lower Target	Neutral	$27.00 ➝ $24.00	Low
3/3/2022	Mizuho	Lower Target	Neutral	$33.00 ➝ $28.00	Low
3/1/2022	JMP Securities	Lower Target	Market Outperform	$42.00 ➝ $35.00	High
3/1/2022	Citigroup	Boost Target		$30.00 ➝ $32.00	High
2/9/2022	HC Wainwright	Upgrade	Neutral ➝ Buy	$18.00 ➝ $36.00	High
1/5/2022	Citigroup	Upgrade	Neutral ➝ Buy	$30.00	High
12/23/2021	SVB Leerink	Reiterated Rating	Buy		Low
12/21/2021	Bank of America	Boost Target	Neutral	$28.00 ➝ $32.00	Medium
12/21/2021	Citigroup	Boost Target	Neutral	$28.00 ➝ $30.00	High
12/21/2021	Royal Bank of Canada	Boost Target	Outperform	$32.00 ➝ $34.00	High
12/21/2021	JMP Securities	Boost Target	Market Outperform	$39.00 ➝ $42.00	High
12/21/2021	Guggenheim	Downgrade	Buy ➝ Neutral	$28.00	High
12/21/2021	Mizuho	Reiterated Rating	Hold		High
12/8/2021	The Goldman Sachs Group	Boost Target	Neutral	$25.00 ➝ $28.00	High
12/7/2021	Morgan Stanley	Boost Target	Equal Weight	$21.00 ➝ $24.00	High
12/7/2021	Oppenheimer	Boost Target	Market Perform	$20.00 ➝ $23.00	High
12/7/2021	JMP Securities	Boost Target	Outperform ➝ Market Outperform	$35.00 ➝ $39.00	High
12/7/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$27.00 ➝ $31.00	High
12/7/2021	Citigroup	Boost Target	Neutral	$25.00 ➝ $28.00	High
12/7/2021	Mizuho	Boost Target	Neutral	$24.00 ➝ $26.00	High
11/9/2021	Citigroup	Boost Target	Neutral	$22.00 ➝ $25.00	High
11/1/2021	Guggenheim	Upgrade	Neutral ➝ Buy	$19.00 ➝ $23.00	High
10/14/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $20.00	High
8/5/2021	Needham & Company LLC	Lower Target	Buy	$30.00 ➝ $26.00	High
8/5/2021	Morgan Stanley	Lower Target	Overweight	$29.00 ➝ $27.00	High
8/5/2021	SVB Leerink	Lower Target	Outperform	$31.00 ➝ $28.00	Medium
8/5/2021	Cantor Fitzgerald	Lower Target	Overweight	$33.00 ➝ $27.00	Medium
7/19/2021	SVB Leerink	Reiterated Rating	Outperform		High
7/10/2021	Raymond James	Set Target		$23.71	Low
7/9/2021	Raymond James	Reiterated Rating	Hold		Low
6/10/2021	Berenberg Bank	Initiated Coverage	Hold	$29.00	High
5/6/2021	Morgan Stanley	Boost Target	Overweight	$28.00 ➝ $29.00	High
5/6/2021	Mizuho	Reiterated Rating	Hold		High
4/13/2021	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Neutral	$73.00 ➝ $25.00	Low
4/13/2021	Jefferies Financial Group	Reiterated Rating	Buy ➝ Hold	$40.00 ➝ $21.00	Low
4/13/2021	Mizuho	Reiterated Rating	Buy ➝ Neutral	$25.00	Low
4/13/2021	HC Wainwright	Reiterated Rating	Buy ➝ Neutral	$43.00 ➝ $18.00	N/A
4/7/2021	HC Wainwright	Downgrade	Buy ➝ Neutral	$43.00 ➝ $18.00	Medium
4/6/2021	SVB Leerink	Lower Target	Outperform	$63.00 ➝ $31.00	Low
4/6/2021	Morgan Stanley	Lower Target	Overweight	$50.00 ➝ $28.00	Low
4/6/2021	Cantor Fitzgerald	Boost Target	Overweight	$33.00 ➝ $45.00	Low
4/6/2021	Mizuho	Downgrade	Buy ➝ Neutral	$37.00 ➝ $25.00	Low
4/6/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$40.00 ➝ $21.00	Low
4/5/2021	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$73.00 ➝ $25.00	High
4/5/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		High
4/5/2021	Needham & Company LLC	Lower Target	Buy	$44.00 ➝ $30.00	High
3/16/2021	Bank of America	Reiterated Rating	Buy ➝ Neutral		High
3/15/2021	Stifel Nicolaus	Reiterated Rating	Buy ➝ Hold	$68.00 ➝ $27.00	N/A
3/15/2021	Raymond James	Reiterated Rating	Strong-Buy ➝ Outperform	$65.00 ➝ $35.00	N/A
3/15/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral		N/A
3/15/2021	Citigroup	Reiterated Rating	Buy ➝ Neutral	$66.00 ➝ $35.00	N/A
3/10/2021	Bank of America	Downgrade	Buy ➝ Neutral		High
3/9/2021	Guggenheim	Downgrade	Buy ➝ Neutral		High
3/9/2021	Morgan Stanley	Lower Target	Overweight	$65.00 ➝ $50.00	High
3/9/2021	Cowen	Lower Target	Outperform	$66.00 ➝ $57.00	High
3/9/2021	Oppenheimer	Lower Target	Market Perform	$42.00 ➝ $28.00	High
3/9/2021	Citigroup	Downgrade	Buy ➝ Neutral	$66.00 ➝ $35.00	High
3/9/2021	Needham & Company LLC	Lower Target	Buy	$60.00 ➝ $44.00	High
3/9/2021	Mizuho	Lower Target	Buy	$70.00 ➝ $55.00	High
3/9/2021	HC Wainwright	Lower Target	Buy	$60.00 ➝ $43.00	High
3/9/2021	Royal Bank of Canada	Lower Target	Outperform	$60.00 ➝ $36.00	High
3/9/2021	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$68.00 ➝ $27.00	High
3/9/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$65.00 ➝ $35.00	High
3/2/2021	Royal Bank of Canada	Boost Target	Outperform	$55.00 ➝ $63.00	High
2/25/2021	Morgan Stanley	Boost Target	Overweight	$60.00 ➝ $65.00	High
2/24/2021	Mizuho	Reiterated Rating	Buy	$69.00 ➝ $70.00	Medium
12/29/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$61.00 ➝ $70.00	N/A
12/16/2020	Morgan Stanley	Boost Target	Overweight	$58.00 ➝ $60.00	Low
12/15/2020	Mizuho	Initiated Coverage	Buy	$69.00	Medium
11/16/2020	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$65.00	High
11/5/2020	Morgan Stanley	Boost Target	Overweight	$57.00 ➝ $58.00	Medium
10/13/2020	Morgan Stanley	Boost Target	Overweight	$55.00 ➝ $57.00	Low
8/24/2020	Raymond James	Initiated Coverage	Outperform	$65.00	Low
8/20/2020	Morgan Stanley	Initiated Coverage	Overweight	$55.00	Medium
8/6/2020	HC Wainwright	Reiterated Rating	Buy		High
8/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$60.00	Low
8/6/2020	SVB Leerink	Lower Target	Outperform	$56.00 ➝ $52.00	Medium
8/6/2020	Oppenheimer	Reiterated Rating	Hold	$42.00	Medium
7/21/2020	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	High
7/21/2020	Citigroup	Lower Target		$69.00 ➝ $63.00	High
7/21/2020	Cantor Fitzgerald	Lower Target	Overweight	$63.00 ➝ $61.00	High
7/21/2020	Oppenheimer	Lower Target	Positive ➝ Market Perform	$53.00 ➝ $42.00	High
7/21/2020	Royal Bank of Canada	Lower Target	Outperform	$61.00 ➝ $55.00	High
7/16/2020	Needham & Company LLC	Initiated Coverage	Buy	$60.00	Low
7/9/2020	Royal Bank of Canada	Boost Target	Positive ➝ Outperform	$58.00 ➝ $61.00	Low
7/6/2020	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$41.00 ➝ $71.00	High
5/27/2020	Oppenheimer	Boost Target	Market Perform	$48.00 ➝ $53.00	Medium
5/8/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$50.00 ➝ $55.00	Medium
5/8/2020	Oppenheimer	Reiterated Rating	Hold	$48.00	High
5/8/2020	Cantor Fitzgerald	Boost Target	Buy	$58.00 ➝ $63.00	High
5/8/2020	Needham & Company LLC	Reiterated Rating	Buy		High
4/16/2020	Jefferies Financial Group	Initiated Coverage	Buy	$60.00	Low
3/31/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$45.00 ➝ $72.00	High
3/5/2020	Citigroup	Initiated Coverage	Buy	$69.00	High
3/5/2020	Cowen	Reiterated Rating	Buy	$66.00	Medium
2/27/2020	HC Wainwright	Reiterated Rating	Buy	$60.00	High
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$70.00 ➝ $75.00	High
2/26/2020	JPMorgan Chase & Co.	Set Target	Outperform	$50.00	Medium
1/19/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
1/14/2020	Cowen	Reiterated Rating	Buy	$66.00	High
12/16/2019	Guggenheim	Initiated Coverage	Buy	$60.00	High
12/5/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	High
12/5/2019	Cowen	Reiterated Rating	Buy	$66.00	High
11/27/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
11/26/2019	Cantor Fitzgerald	Boost Target	Overweight	$63.00 ➝ $70.00	Low
11/26/2019	Cowen	Initiated Coverage	Buy	$66.00	Low
11/26/2019	Royal Bank of Canada	Reiterated Rating	Buy	$60.00	Low
11/26/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	Low
11/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$50.00	Low
11/1/2019	HC Wainwright	Reiterated Rating	Buy	$60.00	Medium
10/24/2019	Oppenheimer	Initiated Coverage	Market Perform	$44.00	Medium
10/1/2019	Royal Bank of Canada	Initiated Coverage	Outperform	$60.00	Low
9/23/2019	Cantor Fitzgerald	Boost Target	Overweight	$49.00 ➝ $56.00	Low
9/13/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$21.00 ➝ $50.00	Low
9/10/2019	HC Wainwright	Set Target	Buy	$60.00	Medium
9/10/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
9/9/2019	Stifel Nicolaus	Set Target	Hold	$39.00	Medium
9/9/2019	Piper Jaffray Companies	Boost Target	Overweight	$35.00 ➝ $56.00	High
9/9/2019	Cowen	Reiterated Rating	Buy	$66.00	Low
9/9/2019	Needham & Company LLC	Boost Target	Buy	$34.00 ➝ $60.00	High
9/3/2019	Stifel Nicolaus	Boost Target	Hold	$24.00 ➝ $28.00	High
8/27/2019	Cantor Fitzgerald	Reiterated Rating	Overweight	$30.00 ➝ $40.00	Low
8/5/2019	Needham & Company LLC	Reiterated Rating	Buy	$34.00	Low
8/1/2019	HC Wainwright	Reiterated Rating	Buy		Low
7/31/2019	JPMorgan Chase & Co.	Set Target	Buy	$32.00	N/A
7/31/2019	Bank of America	Set Target	Buy	$31.00	N/A
7/23/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $34.00	High
7/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
5/31/2019	Raymond James	Boost Target	Strong-Buy	$40.00 ➝ $43.00	Low
5/3/2019	HC Wainwright	Reiterated Rating	Buy		High
5/2/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$31.00	High
4/25/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Medium
3/3/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
2/28/2019	Piper Jaffray Companies	Boost Target	Overweight	$30.00	Low
2/27/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	High
12/5/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$30.00	Low
11/16/2018	UBS Group	Initiated Coverage	Neutral	$39.00	Low
11/12/2018	SVB Leerink	Initiated Coverage	Market Perform	$21.00	High
11/7/2018	Cantor Fitzgerald	Set Target	Buy	$30.00	High
11/3/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
11/1/2018	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$27.00 ➝ $30.00	High
11/1/2018	HC Wainwright	Reiterated Rating	Buy	$60.00	High
10/31/2018	Cantor Fitzgerald	Set Target	Buy	$27.00	High
10/15/2018	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$25.00 ➝ $27.00	High
10/10/2018	Bank of America	Boost Target	Buy ➝ Buy	$22.00 ➝ $25.00	High
10/2/2018	Cantor Fitzgerald	Set Target	Buy	$25.00	Medium
9/21/2018	Piper Jaffray Companies	Initiated Coverage	Positive		High
9/20/2018	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$25.00	High
9/20/2018	Cantor Fitzgerald	Set Target	Buy	$25.00	High
8/29/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$25.00	Low
8/23/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$25.00	High
8/9/2018	JMP Securities	Lower Target	Market Outperform ➝ Market Outperform	$50.00 ➝ $27.00	High
8/9/2018	HC Wainwright	Reiterated Rating	Buy	$60.00	High
8/7/2018	Stifel Nicolaus	Initiated Coverage	Hold ➝ Hold	$17.00	Low
8/6/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$19.00	High
7/1/2018	JPMorgan Chase & Co.	Set Target	Buy	$50.00	Low
5/16/2018	HC Wainwright	Reiterated Rating	Buy		Medium
4/10/2018	JPMorgan Chase & Co.	Set Target	Buy	$50.00	High

(Data available from 3/22/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
5 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

8/24/2022

0 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/23/2022

2 very positive mentions
6 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

10/23/2022

2 very positive mentions
10 positive mentions
2 negative mentions
3 very negative mentions

Mentions as of

11/22/2022

2 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/22/2022

6 very positive mentions
12 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/21/2023

7 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/20/2023

7 very positive mentions
46 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/22/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
3/18/2023
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Post FY2023 Earnings of ($0.49) Per Share, Cantor Fitzgerald Forecasts
americanbankingnews.com
3/18/2023
ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Raised to $15.00 at Jefferies Financial Group
americanbankingnews.com
3/18/2023
StockNews.com Initiates Coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD)
americanbankingnews.com
3/18/2023
Q2 2023 Earnings Estimate for ACADIA Pharmaceuticals Inc. Issued By HC Wainwright (NASDAQ:ACAD)
americanbankingnews.com
3/18/2023
ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Raised to $26.00 at Canaccord Genuity Group

Very Positive

marketbeat.com
3/21/2023
Hennion & Walsh Asset Management Inc. Purchases 8,717 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
msn.com
3/10/2023
Acadia wins FDA nod for Rett syndrome therapy
finance.yahoo.com
3/10/2023
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
marketbeat.com
3/9/2023
Pearl River Capital LLC Acquires 16,131 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
marketbeat.com
3/7/2023
Nuveen Asset Management LLC Cuts Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Today's Range

Now: $18.83

$18.76

$19.39

50 Day Range

MA: $19.36

$17.02

$20.92

52 Week Range

Now: $18.83

$12.24

$28.06

Volume

630,577 shs

Average Volume

1,599,443 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?: The following equities research analysts have issued stock ratings on ACADIA Pharmaceuticals in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Loop Capital, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, StockNews.com, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ACAD.
What is the current price target for ACADIA Pharmaceuticals?: 18 Wall Street analysts have set twelve-month price targets for ACADIA Pharmaceuticals in the last year. Their average twelve-month price target is $21.44, suggesting a possible upside of 13.2%. Cantor Fitzgerald has the highest price target set, predicting ACAD will reach $33.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for ACADIA Pharmaceuticals in the next year.
View the latest price targets for ACAD.
What is the current consensus analyst rating for ACADIA Pharmaceuticals?: ACADIA Pharmaceuticals currently has 2 sell ratings, 6 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACAD, but not buy more shares or sell existing shares.
View the latest ratings for ACAD.
What other companies compete with ACADIA Pharmaceuticals?: Other companies that are similar to ACADIA Pharmaceuticals include Zai Lab, Amicus Therapeutics, IVERIC bio, Reata Pharmaceuticals and Cytokinetics. Learn More about companies similar to ACADIA Pharmaceuticals.
How do I contact ACADIA Pharmaceuticals' investor relations team?: ACADIA Pharmaceuticals' physical mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (858) 558-2871 and its investor relations email address is [email protected] The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com. Learn More about contacing ACADIA Pharmaceuticals investor relations.

ACADIA Pharmaceuticals - ACAD Stock Price Target and Predictions

Analyst Price Target for ACAD

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.41 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?

What is the current price target for ACADIA Pharmaceuticals?

What is the current consensus analyst rating for ACADIA Pharmaceuticals?

What other companies compete with ACADIA Pharmaceuticals?

How do I contact ACADIA Pharmaceuticals' investor relations team?